Event Date: Dec 06, 2023

Recording | Related Resources

In later life, over the last decade, we have come to understand that it is not common for people with dementia to be otherwise well, or even to have neuropathological features only of a single illness. Instead, we see a role for frailty in determining both who gets neuropathological features, and biomarkers, and who expresses these as dementia.
In this, there appears to lie hope, although how much might be achieved by lifestyle factor modification alone seems dubitable.
This presentation will walk through how this understanding has arisen, how we can advise older adults at risk for dementia, and what seems reasonable to tell their middle-aged adult offspring.
This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium on Neurodegeneration in Aging (CCNA).


Dr. Kenneth Rockwood, MD, MPA, FRCPC

Kenneth Rockwood is Professor of Medicine (Geriatric Medicine and Neurology) at Dalhousie and an active staff physician at the Queen Elizabeth II Health Sciences Centre. He serves as the Dalhousie Medical Research Foundation Kathryn Allen Weldon Professor of Alzheimer Research at Dalhousie University. A native of Newfoundland, Ken received his MD from Memorial University, completed internal medicine training at the University of Alberta and Geriatric Medicine at Dalhousie. He is Senior Medical Director for the Frailty and Elder Care Network of Nova Scotia.

A leading authority on frailty, Dr. Rockwood has more than 600 peer-reviewed publications and 9 books to his credit, soon adding the ninth edition of Brocklehurst’s Textbook of Geriatric Medicine & Gerontology. He is Associate Director of the Canadian Collaboration on Neurodegeneration in Aging. 

Since 2017, facilitating his work with the National Health Service of England and Wales, he has held an appointment as Honorary Professor of Population Science and Experimental Medicine, University College London. Ken is President and Co-founder of Ardea Outcomes, a spin-off company that focuses on individualized outcome measurement in several complex diseases.